The U.S. over the counter (OTC) drugs market size accounted for USD 24.81 billion in 2025 and is forecasted to hit around USD 44.17 billion by 2034, representing a CAGR of 6.60% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Over the Counter (OTC) Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Product Type
8.1.1. Vitamin and Dietary Supplements
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Cough & Cold Products
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Analgesics
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Gastrointestinal Products
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Sleep Aids
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Otic Products
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Wart Removers
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. Mouth Care Products
8.1.8.1. Market Revenue and Volume Forecast
8.1.9. Ophthalmic Products
8.1.9.1. Market Revenue and Volume Forecast
8.1.10. Botanicals
8.1.10.1. Market Revenue and Volume Forecast
8.1.11. Antacids
8.1.11.1. Market Revenue and Volume Forecast
8.1.12. Smoking Cessation Products
8.1.12.1. Market Revenue and Volume Forecast
8.1.13. Feminine Care
8.1.13.1. Market Revenue and Volume Forecast
8.1.14. Others
8.1.14.1. Market Revenue and Volume Forecast
9.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Dosage Form
9.1.1. Tablets
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Hard Capsules
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Powders
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Ointments
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Soft Capsules
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Liquids
9.1.6.1. Market Revenue and Volume Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Volume Forecast
10.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Parenteral
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Topical
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. U.S. Over the Counter (OTC) Drugs Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Drug Stores & Retail Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Hospital Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Volume Forecast
12.1. U.S.
12.1.1. Market Revenue and Volume Forecast, by Product Type
12.1.2. Market Revenue and Volume Forecast, by Dosage Form
12.1.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. Bayer AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Takeda Pharmaceutical Company Ltd.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Johnson & Johnson Services Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Sanofi S.A.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Boehringer Ingelheim International GmbH
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. GlaxoSmithKline PLC
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Mylan
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. UPM Pharmaceuticals
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample